更新于：2024-09-06

Silver Nitrate

更新于：2024-09-06

概要

研发状态

概要

基本信息

药物类型

小分子化药

别名

Silver mononitrate、Silver nitrate (JP17/USP)、silver(1+) nitrate

靶点-

作用机制-

治疗领域-

在研适应症-

非在研适应症-

原研机构-

在研机构-

非在研机构-

最高研发阶段批准上市

首次获批日期-

最高研发阶段(中国)批准上市

特殊审评-

结构

分子式AgHNO3

InChIKeyXRRQZKOZJFDXON-UHFFFAOYSA-N

CAS号7761-88-8

关联

项与 Silver Nitrate 相关的临床试验

CTRI/2024/06/068709 / Not yet recruitingN/AIIT

Indirect Pulp Treatment In Young Permanent Molars: 38% Silver Diamine Fluoride (SDF) with and without light cure- A Clinical Control Trial - NIL

开始日期2024-06-22

申办/合作机构-

CTRI/2024/05/068228 / Not yet recruiting临床4期IIT

A study comparing the efficacy of tertiary ammonium compound based foam dressing versus silver based foam dressing in non ischemic diabetic foot ulcer patients using wound ischemia foot infection grading WIFI GRADE 2 in a tertiary care hospital - NIL

开始日期2024-06-12

申办/合作机构-

CTRI/2024/04/065881 / Not yet recruiting临床2/3期IIT

Comparative study between Nanocrystalline silver dressing versus conventional dressings in Diabetic foot ulcers - A randomized control trial - Nil

开始日期2024-04-26

申办/合作机构-

100 项与 Silver Nitrate 相关的临床结果

登录后查看更多信息

100 项与 Silver Nitrate 相关的转化医学

登录后查看更多信息

100 项与 Silver Nitrate 相关的专利（医药）

登录后查看更多信息

3,828

项与 Silver Nitrate 相关的文献（医药）

2024-12-31·Artificial cells, nanomedicine, and biotechnology

Synthesis and characterization of Fe ₃ O ₄ @SiO ₂ @PDA@Ag core–shell nanoparticles and biological application on human lung cancer cell line and antibacterial strains

Article

作者: Singh, Aarushi ; Chugh, Heerak ; Chandra, Ramesh ; Singh, Snigdha ; Roy, Indrajit ; Chakraborty, Nayanika ; Tiwari, Manisha ; Goel, Tanya

Novel magnetic and metallic nanoparticles garner much attention of researchers due to their biological, chemical and catalytic properties in many chemical reactions. In this study, we have successfully prepared a core-shell Fe₃O₄@SiO₂@PDA nanocomposite wrapped with Ag using a simple synthesis method, characterised and tested on small cell lung cancer and antibacterial strains. Incorporating Ag in Fe₃O₄@SiO₂@PDA provides promising advantages in biomedical applications. The magnetic Fe₃O₄ nanoparticles were coated with SiO₂ to obtain negatively charged surface which is then coated with polydopamine (PDA). Then silver nanoparticles were assembled on Fe₃O₄@SiO₂@PDA surface, which results in the formation core-shell nanocomposite. The synthesised nanocomposite were characterized using SEM-EDAX, dynamic light scattering, XRD, FT-IR and TEM. In this work, we report the anticancer activity of silver nanoparticles against H1299 lung cancer cell line using MTT assay. The cytotoxicity data revealed that the IC₅₀ of Fe₃O₄@SiO₂@PDA@Ag against H1299 lung cancer nanocomposites cells was 21.52 µg/mL. Furthermore, the biological data of nanocomposites against Gram-negative 'Pseudomonas aeruginosa' and Gram-positive 'Staphylococcus aureus' were carried out. The range of minimum inhibitory concentration was found to be 115 µg/mL where gentamicin was used as a standard drug. The synthesized AgNPs proves its supremacy as an efficient biomedical agent and AgNPs may act as potential beneficial molecule in lung cancer chemoprevention and antibacterial strains.

2024-05-06·Journal of burn care & research : official publication of the American Burn Association

Utilization of Topical Polysporin and Triamcinolone for the Treatment of Hypergranulation Tissue

Article

作者: Maynell, Kimberly Brown ; Whalen, Kristen ; Smith, David ; Taylor, Loryn ; Bodnar, Michael ; Laun, Jake ; Troy, Jared ; Marek, Jenna ; West, William ; Wright, Benjamin ; Le, Nicole K

Abstract:

Hypergranulation is the abnormal accumulation of granulation tissue in a wound and is commonly seen in burns. It impairs wound healing and can predispose patients to infection. There is no gold standard treatment for hypergranulation tissue, but some options include surgical debridement, chemical cautery with silver nitrate, and topical steroids. Silver nitrate treatment is painful and can lead to scarring, so topical steroid use is on the rise. A retrospective review, between January 1, 2017 and August 30, 2021, at a tertiary burn center was performed to analyze outcomes of hypergranulation tissue after treatment with a topical 50/50 mixture of triamcinolone (Perrigo, Dublin, Ireland) and Polysporin (Johnson & Johnson, New Brunswick, NJ). One hundred and sixteen patients were treated with triamcinolone and Polysporin for hypergranulation tissue, although 24 did not meet inclusion criteria. Eighty-eight out of 92 patients were successfully treated until hypergranulation resolution, while 4/92(4.3%) required silver nitrate or surgery despite the topical cream to achieve resolution. In the 88 patients successfully treated until hypergranulation resolution, 99 areas of hypergranulation were treated. Forty-one of 99 (41.4%) hypergranulation areas resolved within 2 weeks. The average time to hypergranulation resolution was 27.5 ± 2.5 days. We found that a novel 50/50 mixture of triamcinolone and Polysporin topical ointment is an effective and safe treatment for hypergranulation tissue in burn wounds. Further prospective studies are needed to determine its efficacy and safety profile.

2024-04-01·Journal of pediatric urology

The appendix conduit with a conflict of interests – An alternate strategy

Article

作者: Cherian, Abraham ; Akhtarkhavari, Anis ; Ramachandran, Priya ; Shankar Mhaskar, Satej ; Lobo, Sara

INTRODUCTION:

Conventionally the split appendix has been used to address the need for dual conduits such as the Mitrofanoff and the ACE, however limited by its length. We present a video demonstration of an alternate solution.

MATERIAL AND METHODS:

Size-12 Nelaton catheter introduced via appendicular stump and skirted along the lateral wall of the caecum. Ethicon Endopath 35 mm Linear Stapler was used to create a caecal tube of about 3 cm based on the appendicular stump.

RESULTS:

From September 2019-January 2023, 6-patients, aged 5-18 years with a diagnoses of 4-spinal dysraphisms, 1-cloacal anomaly, and 1-urogenital sinus were included.

FOLLOW UP:

5-45 months. Two patients had ACE site infection which resolved with antibiotics. One developed a stomal granuloma treated effectively with silver nitrate. All are clean with no stomal leaks and experience easy intubation.

DISCUSSION:

Alternatives to the split appendix include the Monti ACE, and Caecostomy tube/caecal flap when limited by appendicular length. The technique described is easy and quick however care must be taken to keep away from the ileo-caecal junction and to keep the tube length as short as possible or needed to preserve vascularity.

CONCLUSIONS:

The stapled caecal tube ACE is easy, quick, and safe especially when limited by appendicular length.

项与 Silver Nitrate 相关的新闻（医药）

2024-04-16

·PRNewswire

Journal of the American Chemical Society Differentiates EVŌQ Nano's EVQ-218 Nanoparticle as a New Form of Silver; Holds Promise for Widespread Medical Applications

EVQ-218 is the first stable, nonemissive, pure metal nanoparticle on par with NIST standards for ideal materials. The 'clean and green' EVQ-218 nanosilver is free of toxic ion emissions. SALT LAKE CITY, April 16, 2024 /PRNewswire/ -- EVŌQ Nano, a nanoscience company that engineers novel nanoparticles for the life, materials, and textile science industries, today announced that the American Chemical Society journal, ACS Omega, published a peer-reviewed study characterizing and differentiating the company's lead asset, EVQ-218, as a new form of silver nanoparticle (AgNP). EVQ-218 meets the highest standards set by the National Institute of Standards and Technology (NIST) while avoiding the limitations and safety risks of other nanosilvers. Continue Reading Engineered by EVŌQ Nano, EVQ-218 is the first and only stable, non-ionic silver nanoparticle (AgNP) for medical applications. The characterization of EVQ-218 is timely as the rise of antimicrobial resistance (AMR) has caused a surge of research into safer, more effective treatments. Prioritized by the World Health Organization as one of the top 10 global public health threats, AMR threatens the effective prevention and treatment of infections.1 "The discovery and development of a non-ionic silver nanoparticle represents a pivotal innovation, unlocking the full therapeutic potential of silver without its detrimental trade-offs," said Shaun Rothwell, EVŌQ Nano CEO. While silver's antibacterial qualities have been known for centuries,2,3 it is widely established that the antimicrobial activity is due to ion emission, which poses toxicity risks for biomedical and consumer product applications.4-7 Realizing Silver's Therapeutic Potential Compared to traditional nanosilvers, EVQ-218 is differentiated due to its characterization and behavior as the first stable, nonemissive, pure silver nanoparticle that is on par with NIST standards for ideal materials, making it a superior candidate for biomedical and consumer product use.8 "Not only does EVQ-218 match NIST's standards for particle size and shape, but it possesses an ultrastable shell structure that completely inhibits ion emission — a first for a pure metal nanoparticle," said Bretni Kennon, Ph.D., principal investigator, EVŌQ Nano. Novel Mechanism of Action EVQ-218's antimicrobial efficacy is rooted in its ability to disrupt bacteria's metabolic processes without triggering antimicrobial resistance. EVQ-218 stops bacterial growth by sequestering sulfur. The sequestration of sulfur inhibits metabolic activity within the bacterial cell without compromising cell structures or lysing the cell wall. This blocks activation of bacterial mutations that contribute to AMR. In contrast, nanosilvers with ions rupture cell walls, triggering activation of AMR pathways. Multi-Patented Laser Nanofabrication Process EVQ-218 is a high-energy produced silver nanoparticle with a method of manufacture that avoids chemical or biological synthesis. Ablation via a multiple, cross-laser system occurs at temperatures and pressures akin to diamond formation. The patented single-step, high-volume laser process generates stable, pure metal nanoparticles directly into pharmaceutical-grade water.8 The sub-10 nm spherical nanoparticles have an ultrastable shell structure that inhibits the hallmark ion emission that occurs in other nanosilver species.8 The resulting particle size and shape characteristics prevent the need for stabilizing chemistries.8 When factoring in shelf life, EVQ-218 maintains uniform stability for years; traditional nanosilvers degrade within weeks.8 These properties make EVQ-218 an attractive clean and green alternative to traditional nanosilvers.8 Advancing Antimicrobial Solutions With EVQ-218 To address the critical issue of healthcare-associated infections (HAIs), primarily caused by indwelling devices like catheters, EVŌQ Nano is collaborating with leading catheter manufacturers. By infusing EVQ-218 throughout the polymer, medical devices are extrinsically equipped with antimicrobial protection that has proven to be effective against the most prevalent pathogenic microorganisms. The company is currently targeting the $29 billion catheter market, expected to reach $50 billion by 2031.9 EVŌQ Nano has also received two grants from the Cystic Fibrosis Foundation for the development of an inhaled therapeutic to treat pulmonary bacterial infections. The company had its Pre-Investigational New Drug (pre-IND) meeting with the U.S. Food and Drug Administration (FDA) in March and, with the agency's feedback, is confidently advancing toward Phase I clinical trials. About EVŌQ Nano EVŌQ Nano is a nanoscience company that engineers novel nanoparticles for the life science, materials science, and textile science industries. The company's multi-patented, high-volume laser nanofabrication process creates uniform, sub-10 nm nanoparticles with distinct surface chemistry. These properties represent a significant advancement in nanoscience with the potential for a wide range of applications. To learn more, visit evoqnano.com. Media Contact Capwell Communications [email protected] References Walsh TR, Gales AC, Laxminarayan R, Dodd PC. Antimicrobial resistance: addressing a global threat to humanity. PLoS Med. 2023 Jul 3;20(7):e1004264. doi: 10.1371/journal.pmed.1004264. PMID: 37399216; PMCID: PMC10317217. Alexander JW. History of the medical use of silver. Surg Infect. 2009;10(3):289. Medici S, Peana M, Nurchi VM, Zoroddu MA. Medical uses of silver—history, myths, and scientific evidence. J Med Chem. 2019;62:5923−5943. Stabryla LM, Johnston KA, Millstone JE, Gilbertson LM. Emerging investigator series: it's not all about the ion: support for particle-specific contributions to silver nanoparticle antimicrobial activity Environ Sci Nano. 2018;5:2047−2068. Kedziora A, Speruda M, Krzyzewska E, Rybka J, Bugla-Ploskonska G. Similarities and differences between silver ions and silver in nanoforms as antibacterial agents. Int J Mol Sci. 2018;19:444. Slavin YN, Asnis J, Häfeli UO, Bach H. Metal nanoparticles: understanding the mechanisms behind antibacterial activity. J Nanobiotechnology. 2017;15:65. Liao C, Li Y, Tjong SC. Bactericidal and cytotoxic properties of silver nanoparticles. Int J Mol Sci. 2019;20:449. Kennon BS, Niedermeyer WH. EVQ-218: Characterization of high-energy nanoparticles that measure up to NIST standards. ACS Omega. 2024;9(7):7891-7903. doi: 10.1021/acsomega.3c07745. Darandale M, Talekar D, Deshmukh R. Catheters Market Research, 2031. Allied Market Research. Published May 2022. Accessed December 6, 2023. . SOURCE EVOQ Nano

2024-04-08

·Mass Device

Orthobond wins FDA de novo approval for antibacterial technology that could have vast device applications

The Monmouth Junction, New Jersey-based device developer says it’s the first time the FDA has granted a de novo request for a non-eluting coating designed to actively kill bacteria that could contaminate the surface of a medical device. Orthobond was founded by Princeton University Chemistry Professor Emeritus Jeffrey Schwartz and the late Dr. Gregory Lutz, who was physiatrist-in-chief emeritus at the Hospital for Special Surgery. Lutz died of cancer on March 5, but knew FDA approval was on the horizon. Orthobond CEO David Nichols called the FDA approval a “testament to Gregory’s legacy” in a statement shared with MassDevice. “We are proud to be able to carry it on into this next chapter.” The first application will be Ostaguard-treated SeaSpine Mariner pedicle screws, according to FDA records. Those could be used in patients early next year, Nichols (a former Zimmer Biomet executive) said in an exclusive interview with MassDevice. Orthobond’s proprietary technology is a quaternary ammonium compound coating that’s highly effective in neutralizing the different bacteria responsible for most device-related infections and can be applied to almost any device, he said. Medical Design & Outsourcing: How Orthobond’s antimicrobial coating prevents contamination of medical devices Unlike antibiotic-eluting devices, Ostaguard doesn’t use antibiotics so there’s no risk of creating drug-resistant superbugs. And while antimicrobial materials like silver, palladium and copper can kill bacteria, those toxic metals aren’t biocompatible with human tissue, Nichols said. “Those have been the barriers for decades,” he said. “[Ostaguard] is a brand new category for the FDA. It doesn’t come off the device — it is considered a device — and it actively kills bacteria.” The FDA gave the new category a generic name of “spinal fusion device with quaternary ammonium compound coating,” defined as “a rigid metallic implant device or system comprised of single or multiple components intended to facilitate fusion in skeletally mature patients. The device includes a quaternary ammonium compound coating that is covalently bonded to the device. Where applied, the coating is intended to reduce microbial contamination on the surface of the device prior to implantation. The device does not contain antimicrobial agents that act within or on the body and this device type does not include combination products.” According to an approval letter shared by Ostaguard, the FDA classified the product as a Class II device and established special controls, which Orthobond declined to divulge. While Orthobond said it found no evidence of local or systemic toxicity in sheep, guinea pig and canine testing, the coating technology has not been evaluated in human clinical trials. Orthobond says the technology’s intellectual property is protected through 2037 through three patent fences covering the covalent surface chemistry, antimicrobial layer and analytical processes, including 27 patents and 12 pending applications. Orthobond intends to seek 510(k) clearances for additional orthopedic spinal implant indications before expanding to other fields such as joint reconstruction, oncology, sports medicine, plastic surgery and cardiovascular. “We’re working on a neuromodulation device, there’s a trauma device we’re working on, and we’re going to work on a cochlear implant,” Nichols said. “If you use a cochlear implant and it gets infected, you pretty much lose your hearing. That’s something that they want to solve.” “We’d like to be as broad as possible,” he continued. “… This should be on all devices that get used. There’s no reason why not. If you’re going to sterile package them, why don’t you put an antibacterial on them?” Beyond medtech, Orthobond leaders believe the technology could also have commercial and industrial applications in areas such as automotive, consumer products and textiles. about how Orthobond’s Ostaguard antibacterial technology works and additional potential applications at our sister site, Medical Design & Outsourcing.

上市批准

2024-02-22

·PRNewswire

EVŌQ Nano Announces That Its Antimicrobial Medical Device Platform Demonstrates Success Against the Leading Cause of Healthcare-Associated Infections

Novel Nanoparticle Platform Shows Efficacy Against Antimicrobial Resistance; Potential to Disrupt the $29 Billion Catheter Market SALT LAKE CITY, Feb. 22, 2024 /PRNewswire/ -- EVŌQ Nano, a nanoscience company that engineers novel nanoparticles for the life, material, and textile science industries, today announced its antimicrobial medical device platform has demonstrated effectiveness against the world's leading pathogens implicated in healthcare-associated infections (HAIs), which are some of the most common complications of hospital care. More than 1 million HAIs occur annually in the U.S., causing significant morbidity and mortality. The majority of HAIs are associated with indwelling devices, with catheter-associated urinary tract infections (CAUTIs) representing the most common type.1 Rising antimicrobial resistance has compounded this health threat — as up to one-third of CAUTIs in the U.S. are drug resistant,2 with annual treatment cost exceeding $13 billion.3 "For nearly 30 years, companies have tried to create antimicrobial devices, but the performance never proved effective. Our nanoparticle technology represents an exciting innovation that could profoundly reduce infections associated with medical devices like catheters without contributing to antibiotic resistance," said Shaun Rothwell, CEO of EVŌQ Nano. "With its proven ability to resist microbial growth and biofilm formation without triggering antimicrobial resistance, this platform has the potential to significantly impact device-related infections — much like the antibiotic revolution transformed infectious disease treatment a century ago." By infusing EVŌQ Nano's proprietary nanoparticle, EVQ-218, throughout the polymer itself, medical devices are extrinsically equipped with antimicrobial protection that has proven to be effective against the most prevalent pathogenic microorganisms. The company is currently targeting the $29 billion catheter market, expected to reach $50 billion by 2031.4 Strong Antimicrobial Efficacy In collaboration with the world's leading catheter manufacturers, extensive lab testing on catheters, luers, and fittings manufactured with EVŌQ Nano's EVQ-218 nanoparticle infused throughout the polymer, demonstrated: Strong antibacterial, antifungal, and antibiofilm efficacy Staphylococcus aureus: 7-8 log reduction Pseudomonas aeruginosa: 6-7.5 log reduction Candida albicans: 5-6.5 log reduction Broad-spectrum activity against 64 bacterial strains tested No degradation of antimicrobial activity; sustained presence for the life of the product Novel Mechanism of Action Existing antimicrobial solutions for medical devices have fallen short. Coatings slough off, degrade over time, and can only be applied to limited materials. While silver is a proven and powerful antimicrobial, current antibacterial catheters externally coated with silver lose efficacy once inserted due to natural sloughing of the material coupled with the short life of silver ions. This combination hinders the antimicrobial activity of current products. EVQ-218 is the first and only non-ionic silver nanoparticle. Extensive studies characterize EVQ-218 as a new form of silver nanoparticle (AgNP), manufactured with EVŌQ Nano's multi-patented nanofabrication process that requires only laser energy, ultrapure water, and pure silver metal.5 Unlike standard silver nanoparticles, EVQ-218 has true "bare" silver surface chemistry, with greater group stability that mitigates the need for added stabilizers.5 The discovery and development of a non-ionic silver nanoparticle represents a pivotal innovation, unlocking the full therapeutic potential of silver without its detrimental trade-offs. EVQ-218 delivers high antimicrobial efficacy without ion emissions.6,7 Its efficacy is rooted in EVQ-218's ability to disrupt bacteria's metabolic processes without triggering antimicrobial resistance. EVQ-218 stops bacterial growth by sequestering sulfur. The sequestration of sulfur inhibits metabolic activity within the bacterial cell without compromising cell structures or lysing the cell wall. This avoids activation of bacterial mutations that contribute to antimicrobial resistance. In contrast, nanoparticles with silver ions rupture cell walls, triggering activation of resistance pathways. By incorporating antimicrobial protection into the material manufacturing process, EVŌQ Nano's technology enables the next generation of medical devices to more effectively guard against disease. About EVŌQ Nano EVŌQ Nano is a nanoscience company that engineers novel nanoparticles for the life science, materials science, and textile science industries. The company's multi-patented, high-volume laser nanofabrication process creates nanoparticles that are uniformly sized, surfactant-free, with consistent spherical morphology, and no ion emissions under standard and stressed conditions. These properties represent a significant advancement in nanoscience with the potential for a wide range of applications. To learn more, visit evoqnano.com. Media Contact Capwell Communications [email protected] References Health Care-Associated Infections. Patient Safety Network. Published September 7, 2019. Accessed November 21, 2023. Werneburg GT. Catheter-associated urinary tract infections: current challenges and future prospects. Res Rep Urol. 2022; Apr 4;14:109-133. doi: 10.2147/RRU.S273663. PMID: 35402319; PMCID: PMC8992741 Estimating the additional hospital inpatient cost and mortality associated with selected hospital-acquired conditions. Agency for Healthcare Research and Quality. Content last reviewed November 2017. Accessed January 19, 2024. Darandale M, Talekar D, Deshmukh R. Catheters Market Research, 2031. Allied Market Research. Published May 2022. Accessed December 6, 2023. Kennon BS, Niedermeyer WH. EVQ-218: Characterization of high-energy nanoparticles that measure up to NIST standards. ACS Omega. 2024. doi: 10.1021/acsomega.3c07745 Niedermeyer W, inventor; ATTOSTAT Inc., assignee. Method and apparatus for production of uniformly sized nanoparticles. US patent 9,849,512. November 9, 2017. Dimpka CO, Calder A, Gajjar P, Merugu S, Huang W, Britt DW, McLean JE, Johnson WP, Anderson AJ. Interaction of silver nanoparticles with an environmentally beneficial bacterium, Pseudomonas chlororaphis. J. Haz. Mat. 2011; 188:428-435. doi: 10.1016/j.jhazmat.2011.01.118 SOURCE EVŌQ Nano

100 项与 Silver Nitrate 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01730	-	D08AL01	DB11080

研发状态

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02519738 (CTgov)	临床3期	化脓性肉芽肿	52	Silver Nitrate (Silver Nitrate)	鏇艱淵蓋鑰鹹鬱齋醖構(衊壓憲鏇範繭膚衊簾夢) = 築願網憲鹽積襯遞廠觸鬱壓範鬱膚衊繭夢遞繭 (簾糧膚醖顧餘觸願遞繭, 繭窪獵膚鹹願醖選醖餘 ~ 簾獵膚鹽夢淵構顧醖構) 更多	-	2022-01-25
				Kenalog (Triamcinolone) (Kenalog (Triamcinolone))	鏇艱淵蓋鑰鹹鬱齋醖構(衊壓憲鏇範繭膚衊簾夢) = 膚膚獵鏇鏇窪鏇壓衊淵鬱壓範鬱膚衊繭夢遞繭 (簾糧膚醖顧餘觸願遞繭, 積鹹艱憲廠襯糧糧顧壓 ~ 鹽遞顧齋範鑰廠衊壓獵) 更多
NCT02116608 (CTgov)	临床4期	肉芽肿	26	Betadine	顧衊鏇鹽遞鑰餘淵願壓(範鹽壓鬱範觸鹹簾壓膚) = 觸積壓鹹廠蓋範窪醖簾遞窪繭窪淵積築遞鬱壓 (鑰憲簾鏇鹽繭衊遞顧顧, 顧鹹壓鬱壓廠窪廠壓構 ~ 範鬱選鏇艱鹹襯願衊壓) 更多	-	2021-09-13
AACR2020	N/A	多形性胶质母细胞瘤	-	Silver nanoparticles	鹽製願鏇蓋膚蓋網顧範(膚蓋遞構淵鬱積簾簾鏇) = 獵鏇鏇選憲糧鹹築遞醖網築鏇廠憲鏇壓醖獵鹹 (鏇餘壓簾顧獵憲鑰鏇夢 )	积极	2020-08-15
				Silver nanoparticles + low-level He-Ne laser	鹽製願鏇蓋膚蓋網顧範(膚蓋遞構淵鬱積簾簾鏇) = 糧選鑰獵餘積獵膚獵積網築鏇廠憲鏇壓醖獵鹹 (鏇餘壓簾顧獵憲鑰鏇夢 )
ERS2016	N/A	气肿	12	Silver Nitrate solution 0.5%	顧積淵廠範壓遞蓋積積(醖壓鑰網鑰衊範築窪構) = 衊壓網醖艱簾鏇顧觸築製鹹製願範鹹醖餘願襯 (淵積構膚繭繭壓淵鏇遞 ) 更多	积极	2016-09-01
Pubmed \| J Burn Care Res	N/A	烧伤	89	Silver-Based Burns Dressing	糧壓淵選壓顧範範蓋壓(糧鏇鏇艱範醖範願築鹽) = 膚壓鹹憲窪積糧鹹憲鏇網醖簾遞製夢觸鏇膚願 (窪餘醖鬱願繭壓憲鏇築 )	-	2016-01-01
				Silver-Based Burns Dressing	糧壓淵選壓顧範範蓋壓(糧鏇鏇艱範醖範願築鹽) = 衊築鬱壓鏇鏇襯壓繭網網醖簾遞製夢觸鏇膚願 (窪餘醖鬱願繭壓憲鏇築 )
Pubmed \| J Am Coll Surg	N/A	消化系统疾病	147	Total Occlusive Ionic Silver-Containing Dressing (Ionic silver-containing dressing)	觸糧廠鑰鏇鏇願衊壓選(醖製選壓簾獵鹽鏇艱鬱) = 選鑰艱餘顧窪鹽選蓋顧鑰壓積製蓋艱蓋獵鹹鹽 (觸願窪艱憲鑰觸廠夢醖 )	积极	2015-08-01
				Mupirocin ointment application	觸糧廠鑰鏇鏇願衊壓選(醖製選壓簾獵鹽鏇艱鬱) = 鹹願鹹範壓憲繭膚蓋獵鑰壓積製蓋艱蓋獵鹹鹽 (觸願窪艱憲鑰觸廠夢醖 )
NCT00675922 (Soaks, CTgov)	临床2/3期	烧伤	98	Sulfamylon (Percent Infections:Sulfamylon Site)	網壓網鹹蓋憲糧餘遞窪(糧壓構繭鬱鬱鬱蓋鬱範) = 鹹選獵觸襯醖鑰憲構廠壓觸齋壓壓醖構構艱壓 (憲簾醖艱憲廠廠蓋鹽顧, 糧淵膚積壓鹹衊製淵網 ~ 願願願廠觸鬱簾遞窪鹽)	-	2013-01-18
				Silver Nitrate (Percent Infections: Silver Nitrate Site)	網壓網鹹蓋憲糧餘遞窪(糧壓構繭鬱鬱鬱蓋鬱範) = 鹹鬱壓壓顧遞壓憲鑰醖壓觸齋壓壓醖構構艱壓 (憲簾醖艱憲廠廠蓋鹽顧, 夢憲積網衊網醖艱鏇網 ~ 製鏇積製觸願構簾膚獵)